Literature DB >> 10828873

GVHD dry eyes treated with autologous serum tears.

E M Rocha1, F S Pelegrino, C S de Paiva, A C Vigorito, C A de Souza.   

Abstract

Two cases of GVHD with severe dry eyes are reported where conventional therapy failed to control ocular signs and symptoms. Autologous serum tears, however, resulted in a beneficial clinical effect with marked attenuation of the symptoms. This therapy proved to be safe during 10 months of treatment. Bone Marrow Transplantation (2000).

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10828873     DOI： 10.1038/sj.bmt.1702334

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  26 in total

1.  Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease.

Authors:  S Aoki; H Mizote; A Minamoto; M Suzuki; H K Mishima; H Tanaka
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

2.  An optimised protocol for the production of autologous serum eyedrops.

Authors:  L Liu; D Hartwig; S Harloff; P Herminghaus; T Wedel; G Geerling
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

3.  Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease.

Authors:  Kyung-Sun Na; Man Soo Kim
Journal:  J Ocul Pharmacol Ther       Date:  2012-06-25       Impact factor: 2.671

4.  The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study.

Authors:  Ali Riza Cenk Celebi; Cemalettin Ulusoy; G Ertugrul Mirza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-25       Impact factor: 3.117

5.  Fingerprick autologous blood: a novel treatment for dry eye syndrome.

Authors:  J Than; S Balal; J Wawrzynski; N Nesaratnam; G M Saleh; J Moore; A Patel; S Shah; B Sharma; B Kumar; J Smith; A Sharma
Journal:  Eye (Lond)       Date:  2017-06-16       Impact factor: 3.775

6.  Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting.

Authors:  J T Seki; N Sakurai; S Moldenhauer; J Dam; E G Atenafu; P M Yip; T Mazzulli; T Henderson; J Pendergrast; C Cserti; J P Velazquez; R Simpson; G Felluga; H A Messner; J H Lipton
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

Review 7.  State-of-the-art acute and chronic GVHD treatment.

Authors:  Muhammad Omer Jamil; Shin Mineishi
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

Review 8.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

Review 9.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

Review 10.  Autologous serum eye drops for dry eye.

Authors:  Qing Pan; Adla Angelina; Andrea Zambrano; Michael Marrone; Walter J Stark; Thomas Heflin; Li Tang; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2013-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.